DOCSLIB.ORG

POG) Studies of Acute Myeloid Leukemia (AML): a Review of Four Consecutive Childhood AML Trials Conducted Between 1981 and 2000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
POG) Studies of Acute Myeloid Leukemia (AML): a Review of Four Consecutive Childhood AML Trials Conducted Between 1981 and 2000 Leukemia (2005) 19, 2101–2116 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000 Y Ravindranath1, M Chang2, CP Steuber3, D Becton4, G Dahl5, C Civin6, B Camitta7, A Carroll8, SC Raimondi9 and HJ Weinstein10, for the Pediatric Oncology Group 1Department of Pediatrics, Children’s Hospital of Michigan and Wayne State University, Detroit, MI, USA; 2Department of Statistics, University of Florida, Gainesville, FL, USA; 3Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 5Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA; 6Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Department of Pediatrics, Midwest Children’s Hospital and Medical College of Wisconsin, Milwaukee, WI, USA; 8Department of Genetics, University of Alabama, Birmingham, AL, USA; 9Department of Pathology, St Jude Children’s Hospital, Memphis, TN, USA; and 10Division of Pediatric Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA From 1981 to 2000, a total of 1823 children with acute myeloid Introduction leukemia (AML) enrolled on four consecutive Pediatric Oncology Group (POG) clinical trials. POG 8101 demonstrated that the The general focus of the Pediatric Oncology Group (POG) induction rate associated with the 3 þ 7 þ 7 combination of daunorubicin, Ara-C, and 6-thioguanine (DAT) was greater than acute myeloid leukemia (AML) studies was to explore the that associated with an induction regimen used to treat acute use of cytarabine dose intensification in the treatment for lymphoblastic leukemia (82 vs 61%; P ¼ 0.02). Designed as a childhood AML. In this paper, we review four successive POG pilot study to determine the feasibility of administration of AML studies in which a stepwise dose intensification of noncross-resistant drug pairs and later modified to assess the cytarabine was introduced along with anthracyclines. During effect of dose intensification of Ara-C during the second these studies, we also evaluated the role of autologous and induction course, POG 8498 confirmed the high initial rate of response to DAT (84.2%) and showed that dose intensification of allogeneic bone marrow transplantation (BMT) in first remission Ara-C during the second induction course resulted in a trend in the treatment of childhood AML. Further centralized, toward higher event-free survival (EFS) estimates than did morphology review immunophenotyping and cytogenetic standard-dose DAT (2 þ 5) during the second induction course evaluation was incorporated in successive, thus allowing for (5 year EFS estimates, 22 vs 27%; P ¼ 0.33). Age o2 years and evaluation of prognostic features in large cohorts of childhood leukocyte count o100 000/mm3 emerged as significantly good prognostic factors. The most significant observation made in the AML cases. POG 8498 study was the markedly superior outcome of children Since 1981, four consecutive AML trials have been perfor- with Down’s syndrome who were treated on the high-dose Ara-C med by the POG. Table 1 gives an overview of the number regimen. POG 8821 compared the efficacy of autologous bone of centers involved in three of the four trials, the average marrow transplantation (BMT) with that of intensive consolida- numbers of patients, and the distribution of patients by age at tion chemotherapy. Intent-to-treat analysis revealed similar 5- diagnosis. year EFS estimates for the group that underwent autologous BMT (3674.7%) and for the group that received only intensive Before 1981, patients with AML were treated with regimens chemotherapy (3574.5%) (P ¼ 0.25). There was a high rate of similar to those used to treat childhood acute lymphoblastic treatment-related mortality in the autologous transplantation leukemia (ALL), and the results of the AML treatment were group. The study demonstrated superior results of allogeneic relatively poor. Clinical trials of more intensive regimens BMT for patients with histocompatible related donors (5-year consisting of cytarabine (Ara-C) and anthracycline started with 7 EFS estimate 63 5.4%) and of children with Down’s syndrome the POG 8101 study.1–3 In POG 8101 patients were randomly (5-year EFS estimate, 6678.6%). The POG 9421 AML study þ þ evaluated high-dose Ara-C as part of the first induction course assigned to receive either the 3 7 7 regimen of DAT and the use of the multidrug resistance modulator cyclosporine. (daunorubicin, Ara-C, and 6-thioguinine) or a regimen that Preliminary results showed that patients receiving both high- had been used to treat ALL and included vincristine, dexa- dose Ara-C for remission induction and the MDR modulator for methasone, and Ara-C. The therapy given after remission consolidation had a superior outcome (5-year EFS estimate, induction included a long maintenance phase given over 7 42 8.2%) than did patients receiving other treatment; however, 2 years. the difference was not statistically significant. These four studies demonstrate the importance of dose intensification of The POG 8498 pilot study evaluated the efficacy and toxicity Ara-C in the treatment of childhood AML; cytogenetics as the of high-dose Ara-C given both as a second induction course after single most prognostic factor and the unique curability of AML DAT and as consolidation therapy immediately after the in children with Down’s syndrome. completion of remission induction therapy. Multiagent che- Leukemia (2005) 19, 2101–2116. doi:10.1038/sj.leu.2403927; motherapy after remission induction was modeled after the published online 1 September 2005 VAPA regimen of Weinstein et al.4 The results clearly confirmed Keywords: AML; childhood; treatment; bone marrow the efficacy of the DAT regimen as part of initial induction transplantation; daunorubicin dosing; high-dose cytarabine therapy and established a toxicity profile for high-dose Ara-C in childhood AML.4 In addition, the immunophenotypic charac- Correspondence: Dr Y Ravindranath, Georgie Ginopolis Chair for teristics of childhood AML were analyzed in detail.5 Finally, the Pediatric Cancer and Hematology, Wayne State University School of superior outcome of children with Down’s syndrome treated on Medicine, Children’s Hospital of Michigan-2M34, 3901 Beaubien high-dose Ara-C-containing regimens was first recognized.6 Boulevard, Detroit, MI 48201, USA; Fax: þ 313 745 5237; E-mail: [email protected] POG 8821 compared the efficacy of autologous BMT during Received 8 February 2005; accepted 14 April 2005; published online early remission with that of intensive chemotherapy alone. 1 September 2005 Patients with matched family donors were eligible to proceed Pediatric Oncology Group studies of acute myeloid leukemia Y Ravindranath et al 2102 Table 1 Accrual and follow-up of all patients Trial Period of No. of patients/No. of eligible No. of participating Average no. of patients Average No. of patients accrual patients/No. of eligible patients centers without DS enrolled at each without DS enrolled except those with DS center (range) each year 8101 7/81–1/86 267/264/257 52 4.9 (1–21) 57 8498 7/84–7/88 294/288/274 56 4.9 (1–21) 68 8821 6/88–3/93 666/649/615 88 7.0 (1–22) 130 to allogeneic BMT.7 The outcome of patients who underwent a POG AML protocols- Treatment Schemas autologous BMT as given in this study was not superior to that of Ara-C/TG patients who received only intensive chemotherapy.7 8101-II DAT (3+7)* DAT (2+5) TG/Ara-C/AZ DA The POG 9421 study compared the results of treatment using standard-dose DAT as a first induction course with 8498- I DAT (3+7)* DAT (2+5) HdA+L-Asp (4courses) those of treatment using high-dose Ara-C (1 g/m2 per dose; total, 14 doses), daunorubicin (45 mg/m2 daily for 3 days), and 8498- II DAT (3+7)* HdA HdA X 1 course 6-thioguanine (for 7 days) given as a first induction course. The 6 6 safety and efficacy of an MDR modulator administered during intensification therapy was also investigated. Preliminary results Vp/AZ*- 4 courses of this trial are presented in this paper. POMP*- 4 courses Patients and methods Ara-C Daily x5- 4 courses D = Daunorubicin; A and Ara-C = cytarabine; T, TG = Thioguanine ; AZ = Azacytidine; POMP = Eligibility Mercaptopurine, Oncovin (vincristine), Methotrexate, Prednisolone The main entry criteria of studies 8101, 8498, and 8821 were b Chemotherapy vs ABMT for Childhood AML: POG 8821 age p21 years and previously untreated AML (patients with Treatment Schema secondary AML were eligible if the treatment was for another DAT* type of malignancy); patients with an isolated chloroma were eligible. Patients with myelodysplastic syndrome were not HdA6 eligible, and starting with the POG 8498 study, data of patients Remission (M1 + M2a <15% blasts) with Down’s syndrome were analyzed separately from those of the other patient groups. Randomize For POG 9421, patients with APL were not eligible, and patients with Down’s syndrome were not eligible for random VP/AZ* VP/AZ* VP/AZ* assignment to the groups that received high-dose DAT or cyclosporine (CsA); instead, patients with Down’s syndrome Chemo ABMT AlloBMT were treated with the standard chemotherapy regimen. Chemo = D+ HdA6 DAT VP/AZHdA6 DAT VP/AZ Diagnosis * = IT ara-c X 2 D = Daunorubicin; A = cytarabine; had = high dose cytarabine ; T = Thioguanine ; AZ = Standard French–American–British (FAB) criteria were used in Azacytidine; ABMT= autologous bone marrow transplantation: AlloBMT = allogeneic BMT. IT = the initial diagnosis of AML and its subtypes. Central pathology intrathecal review occurred in all studies. Diagnosis of M0 and M7 subtypes required confirmation by immunologic methods.
Load more

Recommended publications
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • HYDREA Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr HYDREA® Hydroxyurea Capsules, 500 mg USP Antineoplastic Agent Bristol-Myers Squibb Canada Date of Initial Authorization: Montreal, Canada MAR 23, 1979 Date of Revision: AUGUST 10, 2021 Submission Control Number: 250623 HYDREA® (hydroxyurea) Page 1 of 26 RECENT MAJOR LABEL CHANGES 1 Indications 02/2020 7 Warnings and Precautions, Hematologic 08/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................... 22 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................
    [Show full text]
  • Benefit of Intermediate-Dose Cytarabine-Containing Induction In
    Letters to the Editor ter RFS and EFS rates and showed a marked tendency to Benefit of intermediate-dose cytarabine-containing improve the OS of patients with CEBPAdm in both uni- induction in molecular subgroups of acute myeloid variate and multivariable analyses, as shown in Online leukemia Supplementary Table S2. Five-year RFS, EFS, and OS rates were 85%, 81%, and 88% in the intermediate-dose com- The outcome of acute myeloid leukemia (AML) is pared with 56%, 56%, and 68% in the conventional- affected by disease characteristics as well as treatment dose group, respectively (Figure 1). In total, 13 of 75 1-3 regimens. In the CALGB8525 trial, patients with core (17%) patients with CEBPAdm AML underwent allo- binding factor (CBF)-positive leukemia benefited from geneic transplantation in CR1, including five of 32 (16%) 4 consolidation with a high dose of cytarabine. More in the conventional-dose group and eight of 43 (19%) in 2 recently, high-dose daunorubicin (60-90 mg/m ) has the intermediate-dose group. To analyze results in the 5,6 become widely used. High-dose daunorubicin confers a absence of any possible contributory effect of transplan- favorable prognosis for patients with NPM1 muta- tation, patients were censored at the time of transplanta- 1,7,8 tions. tion in CR1. Patients with CEBPAdm AML exposed to Higher-dose cytarabine was also introduced into AML intermediate-dose cytarabine achieved an increase in 5- 3,9 induction therapy. Recently, we investigated the role of year RFS, censored at the date of transplantation, from intermediate-dose cytarabine in induction therapy of 56% to 83% (hazard ratio [HR], 0.313; 95% confidence AML and found that the introduction of intermediate- interval [95% CI]: 0.119-0.824; Wald P=0.019) (Online dose cytarabine, combined with daunorubicin and omac- Supplementary Figure S3).
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]
  • Practical Aspects of the Use of Intrathecal Chemotherapy
    Farmacia Hospitalaria ISSN: 1130-6343 ISSN: 2171-8695 Aula Médica Ediciones (Grupo Aula Médica S.L.) Practical aspects of the use of intrathecal chemotherapy Olmos-Jiménez, Raquel; Espuny-Miró, Alberto; Cárceles-Rodríguez, Carlos; Díaz-Carrasco, María Sacramento Practical aspects of the use of intrathecal chemotherapy Farmacia Hospitalaria, vol. 41, no. 1, 2017 Aula Médica Ediciones (Grupo Aula Médica S.L.) Available in: http://www.redalyc.org/articulo.oa?id=365962303008 DOI: 10.7399/fh.2017.41.1.10616 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative REVISIONES Practical aspects of the use of intrathecal chemotherapy Aspectos prácticos de la utilización de quimioterapia intratecal Raquel Olmos-Jiménez 1 Universidad de Murcia, Spain Alberto Espuny-Miró 1 Universidad de Murcia, Spain Carlos Cárceles-Rodríguez 1 Universidad de Murcia, Spain María Sacramento Díaz-Carrasco 2 Hospital Clínico Universitario Virgen de la Arrixaca, Spain Farmacia Hospitalaria, vol. 41, no. 1, Abstract 2017 Introduction: Intrathecal chemotherapy is frequently used in clinical practice for treatment and prevention of neoplastic meningitis. Despite its widespread use, there is Aula Médica Ediciones (Grupo Aula Médica S.L.) little information about practical aspects such as the volume of drug to be administered or its preparation and administration. Received: 28 July 2016 Accepted: 15 October 2016 Objective: To conduct a literature review about practical aspects of the use of intrathecal chemotherapy. DOI: 10.7399/.2017.41.1.10616 Materials: Search in PubMed/ Medline using the terms “chemotherapy AND intrathecal”, analysis of secondary and tertiary information sources. CC BY-NC-ND Results: e most widely used drugs in intrathecal therapy are methotrexate and cytarabine, at variable doses.
    [Show full text]
  • Genetic Factors Influencing Pyrimidine- Antagonist Chemotherapy
    The Pharmacogenomics Journal (2005) 5, 226–243 & 2005 Nature Publishing Group All rights reserved 1470-269X/05 $30.00 www.nature.com/tpj REVIEW Genetic factors influencing Pyrimidine- antagonist chemotherapy JG Maring1 ABSTRACT 2 Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) HJM Groen and gemcitabine (dFdC), are widely used in chemotherapy regimes for 2 FM Wachters colorectal, breast, head and neck, non-small-cell lung cancer, pancreatic DRA Uges3 cancer and leukaemias. Extensive metabolism is a prerequisite for conversion EGE de Vries4 of these pyrimidine prodrugs into active compounds. Interindividual variation in the activity of metabolising enzymes can affect the extent of 1Department of Pharmacy, Diaconessen Hospital prodrug activation and, as a result, act on the efficacy of chemotherapy Meppel & Bethesda Hospital Hoogeveen, Meppel, treatment. Genetic factors at least partly explain interindividual variation in 2 The Netherlands; Department of Pulmonary antitumour efficacy and toxicity of pyrimidine antagonists. In this review, Diseases, University of Groningen & University Medical Center Groningen, Groningen, The proteins relevant for the efficacy and toxicity of pyrimidine antagonists will Netherlands; 3Department of Pharmacy, be summarised. In addition, the role of germline polymorphisms, tumour- University of Groningen & University Medical specific somatic mutations and protein expression levels in the metabolic Center Groningen, Groningen, The Netherlands; pathways and clinical pharmacology
    [Show full text]
  • A Guide to Safe Handling of Chemotherapy Drugs
    Dynamic Permeation Device A Guide to Safe Handling of Chemotherapy Drugs In order to ensure your maximum protection when In partnership with the Université Catholique de handling cytostatics, Ansell has invested in a totally Louvain, Brussels, Belgium, we have developed new permeation assessment protocol. a unique dynamic permeation device. After dynamic permeation simulation, aliquots of the collecting Because gloves are made to be used under dynamic medium are analysed by LC-MS/MS1 or HPLC-DAD2. physical conditions (stretching, tension, rubbing etc.) some of our products have been tested for cytostatic permeation under the same constraints. Dynamic permeation device. The Molecules Tested are the Following LOD LOQ Analytical (Detection (Quantification Mol. Cytostatic Brand Name Company Method Concentration Limit) Limit) Weight Log P 1 Carmustine Nutrimon BICNU Almirall-Prodesfarma HPLC-DAD 3.0mg/ml 59.02ng/ml 196.73ng/ml 214.0 1.50 2 Cisplatin Platinol Bristol-Myers Squibb HPLC-DAD 1.0mg/ml 49.70ng/ml 165.67ng/ml 300.1 -2,20 3 Cyclophosph- Endoxan AstaMedica LCMS/MS 20.0mg/ml 1.95ng/ml 31.60ng/ml 261.1 0.60 amide 4 Cytarabine Cytosar Pharmacia & UpJohn LCMS/MS 100.0mg/ml 0.97ng/ml 4.93ng/ml 243.2 -2.50 5 Docetaxel Taxotere Aventis Pharma LCMS/MS 10.0mg/ml 3.11ng/ml 17.32ng/ml 807.8 NA 6 Doxorubicin Adriblastina Pharmacia LCMS/MS 2.0mg/ml 35.26ng/ml 55.10ng/ml 543.5 1.30 7 Etoposide Vepesid Bristol-Myers Squibb HPLC-DAD 20.0mg/ml 63.06ng/ml 210.19ng/ml 588.5 0.60 8 5-Fluorouracil Fluoroblastine Pharmacia & UpJohn HPLC-DAD 50.0mg/ml 37.47ng/ml 124.92ng/ml 130.1 -1.00 9 Ifosfamide Holoxan AstaMedica LCMS/MS 100.0mg/ml 4.11ng/ml 45.11ng/ml 261.1 NA 10 Irinotecan Campto Aventis Pharma LCMS/MS 20.0mg/ml 16.32ng/ml 30.73ng/ml 586.6 NA 11 Methotrexate Ledertrexate Wyeth Lederle LCMS/MS 25.0mg/ml 1.41ng/ml 12.85ng/ml 454.4 -1.80 The results contained in this brochure are based on laboratory tests, and reflect the best judgement of Ansell at the time of preparation.
    [Show full text]
  • Acute Myeloid Leukemia (AML) Treatment Regimens
    Acute Myeloid Leukemia (AML) Treatment Regimens Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. uInduction Therapy1 Note: All recommendations are Category 2A unless otherwise indicated. The NCCN believes the best option for any patient with cancer is in a clinical trial and strongly encourages this option for all patients. PATIENT CRITERIA REGIMEN AND DOSING Age <60 years2-8 Days 1–3: An anthracycline (daunorubicin 60–90mg/m2 IV OR idarubicin 12mg/m2) Days 1–7: Cytarabine 100–200mg/m2 continuous IV (Category 1).
    [Show full text]
  • Cancer Drug Costs for a Month of Treatment at Initial Food
    Cancer drug costs for a month of treatment at initial Food and Drug Administration approval Year of FDA Monthly Cost Monthly cost (2013 Generic name Brand name(s) approval (actual $'s) $'s) Vinblastine Velban 1965 $78 $575 Thioguanine, 6-TG Thioguanine Tabloid 1966 $17 $122 Hydroxyurea Hydrea 1967 $14 $97 Cytarabine Cytosar-U, Tarabine PFS 1969 $13 $82 Procarbazine Matulane 1969 $2 $13 Testolactone Teslac 1969 $179 $1,136 Mitotane Lysodren 1970 $134 $801 Plicamycin Mithracin 1970 $50 $299 Mitomycin C Mutamycin 1974 $5 $22 Dacarbazine DTIC-Dome 1975 $29 $125 Lomustine CeeNU 1976 $10 $41 Carmustine BiCNU, BCNU 1977 $33 $127 Tamoxifen citrate Nolvadex 1977 $44 $167 Cisplatin Platinol 1978 $125 $445 Estramustine Emcyt 1981 $420 $1,074 Streptozocin Zanosar 1982 $61 $147 Etoposide, VP-16 Vepesid 1983 $181 $422 Interferon alfa 2a Roferon A 1986 $742 $1,573 Daunorubicin, Daunomycin Cerubidine 1987 $533 $1,090 Doxorubicin Adriamycin 1987 $521 $1,066 Mitoxantrone Novantrone 1987 $477 $976 Ifosfamide IFEX 1988 $1,667 $3,274 Flutamide Eulexin 1989 $213 $399 Altretamine Hexalen 1990 $341 $606 Idarubicin Idamycin 1990 $227 $404 Levamisole Ergamisol 1990 $105 $187 Carboplatin Paraplatin 1991 $860 $1,467 Fludarabine phosphate Fludara 1991 $662 $1,129 Pamidronate Aredia 1991 $507 $865 Pentostatin Nipent 1991 $1,767 $3,015 Aldesleukin Proleukin 1992 $13,503 $22,364 Melphalan Alkeran 1992 $35 $58 Cladribine Leustatin, 2-CdA 1993 $764 $1,229 Asparaginase Elspar 1994 $694 $1,088 Paclitaxel Taxol 1994 $2,614 $4,099 Pegaspargase Oncaspar 1994 $3,006 $4,713
    [Show full text]
  • Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
    cells Review Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Jan Philipp Bewersdorf and Amer M. Zeidan * Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, PO Box 208028, New Haven, CT 06520-8028, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-203-737-7103; Fax: +1-203-785-7232 Received: 19 September 2020; Accepted: 15 October 2020; Published: 17 October 2020 Abstract: Up to 18% of patients with acute myeloid leukemia (AML) present with a white blood cell (WBC) count of greater than 100,000/µL, a condition that is frequently referred to as hyperleukocytosis. Hyperleukocytosis has been associated with an adverse prognosis and a higher incidence of life-threatening complications such as leukostasis, disseminated intravascular coagulation (DIC), and tumor lysis syndrome (TLS). The molecular processes underlying hyperleukocytosis have not been fully elucidated yet. However, the interactions between leukemic blasts and endothelial cells leading to leukostasis and DIC as well as the processes in the bone marrow microenvironment leading to the massive entry of leukemic blasts into the peripheral blood are becoming increasingly understood. Leukemic blasts interact with endothelial cells via cell adhesion molecules such as various members of the selectin family which are upregulated via inflammatory cytokines released by leukemic blasts. Besides their role in the development of leukostasis, cell adhesion molecules have also been implicated in leukemic stem cell survival and chemotherapy resistance and can be therapeutically targeted with specific inhibitors such as plerixafor or GMI-1271 (uproleselan).
    [Show full text]
  • Acronyms for Oncology Regimens
    ACRONYMS AND ABBREVIATIONS OF COMMONLY USED REGIMENS ACRONYM CHEMOTHERAPY COMBINATION 7 + 3 Anthracycline (daunorubicin/idarubicin) or anthracenedione (mitoxantrone)/cytarabine ABV Doxorubicin/ bleomycin/vincristine ABVD Doxorubicin/ bleomycin/vinblastine/dacarbazine AC Doxorubicin/cyclophosphamide ACE Doxorubicin/cyclophosphamide/etoposide AI Doxorubicin/ifosfamide AIDA Tretinoin/idarubicin/dexamethasone/mitoxantrone/6-mercaptopurine/ methotrexate AP Doxorubicin/cisplatin AT Doxorubicin/docetaxel BEACOPP Bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/ prednisone BEP Bleomycin/etoposide/cisplatin BMC Bleomycin/methotrexate/carmustine CAD Cyclophosphamide/doxorubicin/dacarbazine CAP Cyclophosphamide/doxorubicin/cisplatin CAPIRI Capecitabine/irinotecan CAPOX Capecitabine/oxaliplatin CAV Cyclophosphamide/doxorubicin/vincristine CDE Cyclophosphamide/doxorubicin/etoposide CDE-R Cyclophsopahmide/doxorubicin/etoposide/rituximab CECA Cyclophosphamide/etoposide/carboplatin/cytarabine CFAR Alemtuzumab/fludarabine/cyclophosphamide/rituximab CHOEP Cyclophosphamide/doxorubicin/vincristine/etoposide/prednisone CHOP Cyclophosphamide/doxorubicin/vincristine/prednisone CHOP-R Cyclophosphamide/doxorubicin/vincristine/prednisone/rtuximab ChlVPP Chlorambucil/vinblastine/procarbazine/prednisone CMF Cyclophosphamide/methotrexate/5-Fluorouracil CNOP Cyclophosphamide/mitoxantrone/vincristine/prednisone CODOX-M Cyclophsopahmide/vincristine/doxorubicin/cyclophosphamide/methotrexate/ leucovorin/intrathecal cytarabine/intrathecal methotrexate
    [Show full text]